Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation

Simple item page
dc.contributor.authorKumar, S.
dc.contributor.authorPerez, W.
dc.contributor.authorZhang, M.
dc.contributor.authorBallen, K.
dc.contributor.authorBashey, A.
dc.contributor.authorTo, L.
dc.contributor.authorBredeson, C.
dc.contributor.authorCairo, M.
dc.contributor.authorElfenbein, G.
dc.contributor.authorFreytes, C.
dc.contributor.authorGale, R.
dc.contributor.authorGibson, J.
dc.contributor.authorKyle, R.
dc.contributor.authorLacy, M.
dc.contributor.authorLazarus, H.
dc.contributor.authorMcCarthy, P.
dc.contributor.authorMilone, G.
dc.contributor.authorMoreb, J.
dc.contributor.authorPavlovsky, S.
dc.contributor.authorReece, D.
dc.contributor.authoret al.
dc.date.issued2008
dc.descriptionCopyright © 2008 American Society for Blood and Marrow Transplantation Published by Elsevier Inc.
dc.description.abstractNonsecretory myeloma (NSM) accounts for <5% of cases of multiple myeloma (MM). The outcome of these patients following autologous stem cell transplantation (ASCT) has not been evaluated in clinical trials. We compared the outcomes after ASCT for patients with NSM reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 1989 and 2003, to a matched group of 438 patients (4 controls for each patient) with secretory myeloma (SM). The patients were matched using propensity scores calculated using age, Durie-Salmon stage, sensitivity to pretransplant therapy, time from diagnosis to transplant, and year of transplant. Disease characteristics were similar in both groups at diagnosis and at transplant except higher risk of anemia, hypoalbuminemia, and marrow plasmacytosis (in SM) and plasmacytoma (more in NSM). Cumulative incidence of treatment-related mortality (TRM), relapse, progression-free survival (PFS), and overall survival (OS) were similar between the groups. In multivariate analysis, based on a Cox model stratified on matched pairs and adjusted for covariates not considered in the propensity score, we found no difference in outcome between the NSM and SM groups. In this large cohort of patients undergoing ASCT, we found no difference in outcomes of patients with NSM compared to those with SM.
dc.description.statementofresponsibilityShaji Kumar, Waleska S. Pérez, Mei-Jie Zhang, Karen Ballen, Asad Bashey, L. Bik To, Christopher N. Bredeson, Mitchell S. Cairo, Gerald J. Elfenbein, César O. Freytes, Robert Peter Gale, John Gibson, Robert A. Kyle, Martha Q. Lacy, Hillard M. Lazarus, Philip L. McCarthy, Gustavo A. Milone, Jan S. Moreb, Santiago Pavlovsky, Donna E. Reece, David H. Vesole, Peter H. Wiernik and Parameswaran Hari
dc.description.urihttp://www.elsevier.com/wps/find/journaldescription.cws_home/670590/description#description
dc.identifier.citationBiology of Blood and Marrow Transplantation, 2008; 14(10):1134-1140
dc.identifier.doi10.1016/j.bbmt.2008.07.011
dc.identifier.issn1083-8791
dc.identifier.issn1523-6536
dc.identifier.urihttp://hdl.handle.net/2440/52527
dc.language.isoen
dc.publisherCarden Jennings Publ Co Ltd
dc.source.urihttps://doi.org/10.1016/j.bbmt.2008.07.011
dc.subjectHumans
dc.subjectMultiple Myeloma
dc.subjectRecurrence
dc.subjectTreatment Outcome
dc.subjectHematopoietic Stem Cell Transplantation
dc.subjectTransplantation, Autologous
dc.subjectAnalysis of Variance
dc.subjectSurvival Analysis
dc.subjectRetrospective Studies
dc.subjectAdult
dc.subjectMiddle Aged
dc.titleComparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Pathology publications